Entrada Therapeutics, Inc. (TRDA) Discusses On Home With HCW Call (Transcript) [Seeking Alpha]
Entrada Therapeutics, Inc. (TRDA)
Company Research
Source: Seeking Alpha
Dipal Doshi - CEO & Director Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Presentation Raghuram Selvaraju H.C. Wainwright & Co, LLC, Research Division My name is Raghuram Selvaraju. I'm a Managing Director and Senior Health Care Equity Research Analyst here within the Equity Research Department at H.C. Wainwright & Company. I'm joined today by Dipal Doshi, Chief Executive Officer of Entrada Therapeutics. Entrada is traded on the NASDAQ under the ticker symbol TRDA, and we cover Entrada with a buy rating and 12-month price target of $20 per share. Dipal, it's a pleasure to have you with us today. Dipal Doshi CEO & Director Ram, I appreciate the opportunity and look forward to the discussion. Question-and-Answer Session Raghuram Selvaraju H.C. Wainwright & Co, LLC, Research Division So perhaps we could start by having you give our audience a brief overview of Entrada Therapeutics and in particular, the Endoso
Show less
Read more
Impact Snapshot
Event Time:
TRDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRDA alerts
High impacting Entrada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRDA
News
- Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts [Seeking Alpha]Seeking Alpha
- Entrada Therapeutics (NASDAQ:TRDA) was given a new $13.00 price target on by analysts at Roth Capital.MarketBeat
- Entrada Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
TRDA
Earnings
- 11/6/25 - Miss
TRDA
Sec Filings
- 12/4/25 - Form EFFECT
- 11/25/25 - Form SCHEDULE
- 11/24/25 - Form 4
- TRDA's page on the SEC website